Brief: Virpax Pharmaceuticals Announces That Envelta Remains On Track For Trial In Humans Following FDA Review
31/10/2023 13:01
Oct 31 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS ANNOUNCES THAT ENVELTA™ REMAINS ON
TRACK
FOR TRIAL IN HUMANS FOLLOWING FDA REVIEW
* VIRPAX PHARMACEUTICALS INC - EXPECTS TO SUBMIT IND FOR
ENVELTA
IN MID-2024 FOLLOWING REVIEW OF COMMENTS MADE BY US FDA ON
COMPANY'S PRE-IND SUBMISSION
Source text for Eikon: ID:nBw9R0zyYa
Further company coverage: VRPX.O
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study